of the metabolic syndrome and atrial fibrillation. Although HFpEF-PH patients fulfilled the criteria for out-of-proportion PH, with transpulmonary gradient (TPG) 1 12 mm Hg, the difference between the diastolic PAP and the pulmonary capillary wedge pressure (PCWP) was significantly lower compared to IPAH (6.3 8 6.2 vs. 27.5 8 4.8, p ! 0.00001). Conclusions: Our results suggest that a diagnosis of HFpEF-PH should be suspected when severe PH occurs in an elderly postmenopausal female with one or more features of the metabolic syndrome and atrial fibrillation. Interestingly, these patients had significantly lower differences between diastolic PAP and PCWP, suggesting that the increase in TPG is mainly caused by an elevated systolic PAP, possibly as a result of increased pulmonary vascular stiffness, and not pulmonary vascular remodeling.
Introduction
Pulmonary hypertension (PH) is defined by a mean pulmonary artery pressure (mPAP) 6 25 mm Hg at rest measured during right-sided heart catheterization (RHC) [1] [2] [3] [4] . Group 1 of the recently updated PH clinical classification, namely pulmonary arterial hypertension (PAH), is a rare disease causing precapillary PH (mPAP 6 25 mm Hg) in the presence of a normal pulmonary capillary wedge pressure (PCWP ^ 15 mm Hg). A more frequent scenario is a patient presenting with PH in the setting of left heart disease characterized by elevated leftsided cardiac filling pressure as assessed by PCWP or left ventricular end-diastolic pressure (LVEDP). This is commonly termed pulmonary venous hypertension, and these patients fall within group 2 of the PH clinical classification [1] [2] [3] [4] .
Heart failure with preserved ejection fraction (HFpEF) is a clinical syndrome characterized by the symptoms and signs of heart failure (HF) and preserved ejection fraction (EF), and it is often related to abnormal LV diastolic function [5] . The prevalence of HFpEF increases with age and represents around half of the whole HF population [6, 7] . PH in conjunction with HFpEF is less studied and the optimal treatment of this condition is unknown, although recent studies suggest that PH is highly prevalent [6, 7] .
Metabolic syndrome (MS), as defined by the current National Cholesterol Education Program Adult Treatment Panel III, is composed of a cluster of risk factors including impaired fasting glucose levels, elevated blood pressure and triglyceride levels, and increased waist circumference [8] . MS is becoming increasingly common, affecting 22% of the adult population in industrialized countries and over 40% of those aged 50 years and older [9, 10] . Individuals with the MS and normal LV systolic function are frequently found to have LV diastolic dysfunction. Previous studies identified that the components of the MS such as hypertension and obesity are independent predictors of the development of HFpEF [11, 12] . Whether the presence of MS also causes an increased risk of pulmonary vascular disease is unknown, although recent studies suggest that this may be a plausible hypothesis [13, 14] .
Severe PH is increasingly recognized in the elderly population [15, 16] . The elevation of pulmonary artery pressure (PAP) which is considered to be out of proportion in relation to that expected from the elevation of left arterial pressure is defined by a transpulmonary gradient (TPG) (mPAP -PCWP) 1 12 mm Hg and pulmonary vascular resistance (PVR) above 3.0 Wood units [1] [2] [3] [4] . In the present study we aimed to assess the clinical and hemodynamic characteristics of this subgroup of elderly patients with HFpEF and out-of-proportion PH (HFpEF-PH). For that purpose, we retrospectively reviewed the charts of patients with HFpEF-PH and compared their clinical characteristics and hemodynamic data to those of age-matched patients diagnosed with idiopathic PAH (IPAH).
Methods

Subjects
We retrospectively reviewed the charts of patients followed between 2008 
HFpEF Diagnosis
The diagnosis of HFpEF was made according to the 2007 consensus statement of the Heart Failure and Echocardiography Association of the ESC and required the following three characteristics: signs and symptoms of HF, normal or mildly abnormal LV systolic function (LVEF 6 50%), and evidence of LV diastolic dysfunction noninvasively by echocardiogriography, and it was confirmed by demonstrating high left side filling pressures (PCWP 1 15 mm Hg) on RHC [17] .
Evaluation of PH
All patients were evaluated using ERS/ESC guidelines to determine the presence, severity, and etiology of PH [1] [2] [3] [4] 18] . Patients who had any of the following conditions were excluded: congenital heart diseases, connective tissue diseases, HIV infection, portal hypertension, appetite suppressant exposure, chronic hypoxic lung disease, and chronic thromboembolic disease.
RHC was performed using a standard protocol. Inhaled nitric oxide up to 10 ppm for 10 min was used to assess acute vasodilator response. Acute vasodilator responsiveness was defined according to published criteria [2] [3] [4] 19] .
Statistical Analysis
Data are presented as numbers or means and categorical variables as numbers, percentages, or proportions. The independentsamples t test was used to compare continuous variables, and 2 tests were used to compare categorical variables. Fisher's exact test was used in cases of small sample sizes. p ! 0.05 was considered statistically significant. SPSS statistical software was used to perform all statistical analyses. 
Results
Clinical Characteristics
Twenty consecutive patients with HFpEF-PH and 20 age-matched IPAH patients were included in the study. The mean age was 71.3 8 7.8 and 70.2 8 6.7 years, respectively. The clinical characteristics of the patients are presented in table 1 .
Most HFpEF-PH patients were females (16 out of 20; 80%), as compared to only 6 out of 20 (30%) age-matched elderly IPAH patients.
HFpEF-PH patients were commonly overweight or obese, but there was no statistical difference with agematched IPAH patients (BMI = 31.0 8 6.8 vs. 28.2 8 3.2, p = 0.1).
HFpEF-PH patients had a higher prevalence of systemic hypertension and diabetes which were significantly more common in comparison to the IPAH group (p = 0.0004 and p = 0.05, respectively). Hyperlipidema was also very common in HFpEF-HF patients (data not available in the IPAH group).
Persistent or paroxysmal atrial fibrillation was significantly more common in patients with HFpEF-PH compared to IPAH patients (85 vs. 15%, p ! 0.00001).
Hemodynamic Characteristics
The hemodynamic characteristics of the patients are presented in table 2 . HFpEF-PH and IPAH patients had severe PH (mPAP = 50.2 8 7.1 and 50.2 8 9.5, respectively, p = 1.0). The average PCWP was significantly higher in the HFpEF-PH patients compared to the IPAH patients (22.8 8 4.4 vs. 9.6 8 3.1 mm Hg, respectively, p ! 0.00001). Right atrial pressure (RAP) was significantly higher in the HFpEF-PH patients (14.8 8 4.9 vs. 10.7 8 5.6 mm Hg, p = 0.01). The SPAP and diastolic PAP (DPAP) and the pulmonary pulse pressure were similar in the two groups. By contrast, the TPG was markedly higher in the IPAH patients, as was the difference between the DPAP and the PCWP (40.5 8 8.8 and 22.0 8 7.8 mm Hg vs. 27.5 8 4.8 and 6.3 8 6.2 mm Hg, p ! 0.00001, respectively). The PVR was significantly higher in the IPAH patients as compared to the HFpEF-PH patients (p = 0.0005). Interestingly, a positive response to inhaled nitric oxide was observed in 10% of patients in both groups.
Echocardiography Data
The echocardiography data is presented in table 3 . The typical finding on echocardiography in the HFpEF-PH group was preserved systolic LV function with borderline intraventricular septum hypertrophy and left atrial dilatation, suggesting the diagnosis of HFpEF.
Discussion
The main finding of our study is that in elderly patients with HFpEF and severe PH on echocardiography, out-of-proportion PH is a major differential diagnosis of IPAH and has to be clarified by RHC. Some patient's characteristics are in favor of a diagnosis of HFpEF-PH. In our study, a typical HFpEF-PH patient was a 70-yearold female with chronic atrial fibrillation and features of MS such as morbid obesity, systemic hypertension, diabetes mellitus, and hyperlipidemia. The typical hemodynamic characteristics include markedly elevated SPAP, with high pulmonary pulse pressure similar to that in IPAH patients but with lower TPG and a significantly lower difference between DPAP and PCWP than in IPAH patients.
The prevalence of HFpEF increases with age and, in patients 1 70 years of age, it may affect around 50% of the population [6, 7] . It is more common among women, and major risk factors include systemic hypertension, ischemic heart disease, diabetes, and obesity [20] [21] [22] .
Echocardiography is the main diagnostic tool in the evaluation of diastolic dysfunction. However, in patients with chronic atrial fibrillation, assessment of the LV diastolic function is difficult [17, 23, 24] . Tissue Doppler echocardiography is a more reliable tool for further evaluation of diastolic dysfunction. The findings of an enlarged left atrium and borderline hypertrophy of the intraventricular septum and LV posterior wall in our cohort of patients in the presence of preserved LVEF support the diagnosis of HFpEF.
Interestingly, 80% (16 out of 20) of the HFpEF-PH patients were obese postmenopausal women, in contrast to only 30% of the IPAH group. It is well known that in an unselected IPAH population the female/male ratio is 1.7: 1 and that the mean age at diagnosis is around 40-50 years [2] [3] [4] 15] . However, recent studies suggest that the age range of affected individuals may be wider than expected, as cases of IPAH, now days, have been reported in many patients older than 70 years [15, 25] . Whether IPAH is more common in males in the older population deserves further investigation but was already reported in the French registry [15] . A recently published study also found a strong association of HFpEF-PH with female gender, similar to a cohort of patients with PAH [26] . However, in contrast to our study, the PAH patient group was significantly younger and not matched by age, suggesting that in elderly patients with IPAH male gender is more predominant.
One of the major findings in our study is the high prevalence of features of MS in the HFpEF-PH patients as opposed to the IPAH patients. Most of the HFpEF-PH patients were obese postmenopausal women with an average BMI of 31, and 80% of the patients had hyperlipidemia and systemic hypertension while 17 out of 20 patients had diabetes mellitus. Interestingly, our agematched IPAH population was also overweight (BMI 28.2 8 3.2), which was not significantly different from the HFpEF-PH group.
The relationship of the MS with HFpEF is increasingly recognized [20] [21] [22] 27] . The question which arises is whether patients, especially women, with two or more features of the MS are prone to develop not only diastolic dysfunction but also severe and out-of-proportion PH. Robbins et al. [14] also described 17 patients (77% female) with diastolic dysfunction and PH characterized by two or more features of MS. Rifaie et al. [28] showed similar findings -the development of PH in patients with HFpEF was independently associated with obesity (BMI 1 40), atrial arrhythmias, and age 1 80 years. A recently published study also found that, compared with PAH, HFpEF-PH is associated with more advanced age, diabetes, obesity, hypertension, and coronary artery disease [26] .
Diabetes mellitus and systemic hypertension were significantly more prevalent in the HFpEF-PH group than in IPAH patients.
Systemic hypertension and peripheral vascular stiffness are known as independent risk factors for the development of HFpEF. Furthermore, recent studies demonstrated that MS amplifies the age-associated increases in vascular thickness and stiffness [29, 30] . Interestingly, the HFpEF-PH group was characterized by high SPAP and relatively low DPAP, with a significantly lower difference between the DPAP and PCWP, when compared to the age-matched IPAH patients. A similar phenomenon was reported in a recent study [31] describing the clinical and hemodynamic characteristics of 239 patients with HFpEF and PH. Although this group of patients fulfilled the definition of disproportionate PH, with a mean TPG of 12.4 mm Hg, their SPAP was relatively higher than the DPAP, which was similar to the LVEDP (22.2 8 6.8 vs. 22.7 8 5.8 mm Hg). One explanation for the preferential increase in SPAP might be increased pulmonary vascular stiffness. As in the systemic circulation, the pulmonary vasculature may be affected by age-associated arterial remodeling [32] [33] [34] [35] , leading to pulmonary vascular stiffness and increases in SPAP. A recent population-based study [36] demonstrated that PAP increases with age. The increase in PAP, estimated by echocardiography, correlated with increases in pulse pressure and estimated left heart filling pressures, suggesting that age-associated blood vessel stiffening and diastolic dysfunction contribute to changes in PAP. Furthermore, elevated SPAP was associated with an increase in all-cause mortality independently of both age and the presence of clinically evident cardiopulmonary disease. It seems that vascular stiffness reflected as increased systemic vascular resistance not only contributes to the development of isolated systolic hypertension and HFpEF but may also affect the pulmonary vasculature, leading to mainly increased SPAP with a higher pulse pressure, a relatively lower DPAP, and a modest increase in PVR as in our HFpEF-PH patients. In contrast, IPAH patients had both a significantly higher difference between the DPAP and PCWP and higher PVR, similar to the findings reported by Thenappan et al. [26] . Furthermore, in our HFpEF-PH patients, the difference between DPAP and PCWP was low, suggesting that pulmonary vascular remodeling and increased PVR was not a major cause of severe PH in these patients, contrasting with our findings in IPAH. It also raises the question of whether the current hemodynamic definition of 'out-of-proportion' PH is misleading. The TPG may be augmented by increased PVR or a change in pulmonary vascular compliance. In our HFpEF-PH patients it seems that the main reason for the severely increased SPAP is increased pulmonary vascular stiffness and reduced compliance, which may explain the increased TPG (although lower than the TPG in the IPAH patients), but with only a mild increase in DPAP. Hence, the difference between DPAP and PCWP might better reflect out-of-proportion PH as compared to the TPG and may be considered in future PH hemodynamic guidelines [37] [38] [39] .
Interestingly, 2 patients with HFpEF-PH had a positive response to inhaled nitric oxide. Although expected, no increase in wedge pressure was observed during nitric oxide inhalation. Whether these patients have a component of increased vascular reactivity, explaining the observed response, is currently unknown. Of note, RAP was also significantly higher in HFpEF-PH patients. This may reflect volume overload in this patient group and is consistent with the corresponding elevated left heart pressures.
In summary, we suggest that a diagnosis of HFpEF with out-of-proportion PH be considered when elevated PAP is investigated in an elderly female with features of MS, atrial fibrillation, and echocardiography findings of preserved EF, a dilated left atrium, and markers of diastolic dysfunction. Chronic increases in pulmonary venous pressure in combination with individual (possibly genetic) predisposition and combined metabolic and inflammatory changes induced by MS, all acting in concert to increase vascular systemic and pulmonary stiffness, may contribute to the development of clinical out-of-proportion PH. The current definition of out-ofproportion PH might be misleading since the increase in TPG is mainly due to the elevated SPAP and the difference between DPAP and the PCWP is low, suggesting that the increase in TPG is not due to pulmonary vascular remodeling and increased PVR but rather to increased pulmonary vascular stiffness. Therefore, the current definition might be reconsidered and could include an increased difference between DPAP and PCWP. Further studies are needed to investigate the effects of the MS on the pulmonary circulation, and to evaluate the best therapeutic approach in patients with HFpEF, severe PH, and the MS, bearing in mind that currently approved PAH therapies have not been properly tested in this population and should thus not be proposed in that setting before demonstration of their effects in adequately powered randomized placebo-controlled trials.
